Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
The Lancet Neurology,  Clinical Article

Farkkila M et al. – Oral lasmiditan seems to be safe and effective in the acute treatment of migraine. Further assessment in larger placebo–controlled and triptan–controlled trials are needed to assess the potential role of lasmiditan in acute migraine therapy.

Methods
  • In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo.
  • Study drug and placebo were supplied in identical numbered tablet packs.
  • The randomisation code was generated by an independent statistician.
  • Patients and investigators were masked to treatment allocation.
  • The primary endpoint was dose response for headache relief (moderate or severe becoming mild or none) at 2 h.
  • The primary analysis was done in the modified intention-to-treat population.

Results
  • Between July 8 2009, and Feb 18, 2010, 512 patients were randomly assigned to treatment, 391 of whom received treatment.
  • 86 patients received placebo (81 included in primary analysis) and 305 received lasmiditan (50 mg n=79, 100 mg n=81, 200 mg n=69, and 400 mg n=68 included in primary analysis).
  • There was a linear association between headache response rate at 2 h and lasmiditan dose (Cochran-Armitage test p<0.0001).
  • Every lasmiditan treatment dose significantly improved headache response at 2 h compared with placebo (lasmiditan 50 mg: difference 17.9%, 95% CI 3.9-32.1, p=0.022; 100 mg: 38.2%, 24.1-52.4, p<0.0001; 200 mg: 28.8%, 9.6-39.9, p=0.0018; 400 mg: 38.7%, 23.9-53.6, p<0.0001).
  • The proportion of patients with treatment-emergent adverse events increased with increasing doses (53/82 [65%], 59/82 [72%], 61/71 [86%], and 59/70 [84%] for lasmiditan 50, 100, 200, and 400 mg, respectively vs 19/86 [22%] for placebo).
  • Most adverse events were mild or moderate in intensity, with 16 of 82 (20%), 23 of 82 (28%), 28 of 71 (39%), and 31 of 70 (44%) of patients on lasmiditan 50, 100, 200, and 400 mg, respectively reporting a severe adverse event compared with five of 86 (6%) on placebo.
  • The most common adverse events were CNS related and included dizziness, fatigue, vertigo, paraesthesia, and somnolence.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Family Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Family Medicine Articles

1 Effect of caffeine on exercise capacity and function in prostate cancer survivors Medicine and Science in Sports and Exercise, July 9, 2014    Clinical Article

2 Circumcision plus antibiotic, anti-inflammatory, and α-blocker therapy for the treatment for chronic prostatitis/chronic pelvic pain syndrome: A prospective, randomized, multicenter trial World Journal of Urology, July 16, 2014    Clinical Article

3 Changes in circulating leptin levels during acute stress and associations with craving in abstinent smokers: A preliminary investigation Psychoneuroendocrinology, June 20, 2014    Clinical Article

4 Vasectomy may increase risk of aggressive prostate cancer Harvard Gazette - Health News, July 11, 2014

5 Treating concurrent chronic low back pain and depression with low-dose venlafaxine: an initial identification of easy-to-use clinical predictors of early response Pain Medicine, July 8, 2014    Clinical Article

6 Physical activity motivation mediates the association between depression symptoms and moderate-to-vigorous physical activity Preventive Medicine, July 2, 2014    Clinical Article

7 Yoga as an adjunctive treatment for posttraumatic stress disorder: a randomized controlled trial The Journal of Clinical Psychiatry, July 7, 2014    Clinical Article

8 Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason Score (GS = 8-10) predict pathologic outcome in radical prostatectomy Human Pathology, July 22, 2014    Review Article

9 Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications BMJ, July 3, 2014    Evidence Based Medicine

10 Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals American Journal of Clinical Nutrition, July 8, 2014    Evidence Based Medicine

11 Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 Trial Full Text European Urology, July 18, 2014    Free full text    Clinical Article

12 Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study Journal of Affective Disorders, July 16, 2014    Clinical Article

13 Tea consumption and leukemia risk: A meta-analysis Tumor Biology, February 12, 2014    Evidence Based Medicine    Clinical Article

14 The effect of green tea on blood pressure and lipid profile: A systematic review and meta-analysis of randomized clinical trials Nutrition, Metabolism & Cardiovascular Diseases, March 27, 2014    Evidence Based Medicine    Review Article

15 Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: A randomized noninferiority controlled trial with long-term results at 6 years Full Text European Urology, July 28, 2014    Free full text    Clinical Article

16 Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies CNS Spectrums, July 1, 2014    Clinical Article

17 Tea consumption and the risk of five major cancers: A dose-response meta-analysis of prospective studies Full Text BMC Cancer, March 18, 2014    Free full text    Evidence Based Medicine    Review Article

18 Prospective study of breakfast eating and incident coronary heart disease in a cohort of male US health professionals Full Text Circulation, July 24, 2013    Free full text    Clinical Article

19 Coffee consumption and prostate cancer risk: An updated meta-analysis Cancer Causes and Control, March 3, 2014    Evidence Based Medicine    Clinical Article

20 A prospective, blinded comparison of magnetic resonance (MR) imaging–ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: The PROFUS trial Full Text European Urology, July 14, 2014    Free full text    Clinical Article

Indexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Medmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close